AbbVie banishes the ghost of Stemcentrx
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.
New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.
First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.
Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.
In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.
Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.